These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 26501462)

  • 1. Routes for Drug Delivery to the Eye and Retina: Intravitreal Injections.
    Meyer CH; Krohne TU; Charbel Issa P; Liu Z; Holz FG
    Dev Ophthalmol; 2016; 55():63-70. PubMed ID: 26501462
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Lid splinting eyelid retraction technique: a minimised sterile approach for intravitreal injections.
    Munro M; Williams GR; Ells A; Fielden M; Kherani A; Mitchell P; Ruzicki J; Adatia FA
    Br J Ophthalmol; 2018 Sep; 102(9):1254-1258. PubMed ID: 29246893
    [TBL] [Abstract][Full Text] [Related]  

  • 3. National survey of the ophthalmic use of anti-vascular endothelial growth factor drugs in Israel.
    Waisbourd M; Goldstein M; Loewenstein A
    Isr Med Assoc J; 2011 Mar; 13(3):141-6. PubMed ID: 21608333
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survey: technique of performing intravitreal injection among members of the Brazilian Retina and Vitreous Society (SBRV).
    Shiroma HF; Farah ME; Takahashi WY; Gomes AM; Goldbaum M; Rodrigues EB
    Arq Bras Oftalmol; 2015; 78(1):32-5. PubMed ID: 25714535
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bimanual assisted eyelid retraction technique for intravitreal injections.
    Fineman MS; Hsu J; Spirn MJ; Kaiser RS
    Retina; 2013 Oct; 33(9):1968-70. PubMed ID: 23609121
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Safety study of 38,503 intravitreal ranibizumab injections performed mainly by physicians in training and nurses in a hospital setting.
    Hasler PW; Bloch SB; Villumsen J; Fuchs J; Lund-Andersen H; Larsen M
    Acta Ophthalmol; 2015 Mar; 93(2):122-5. PubMed ID: 25403735
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Eliminating antibiotic prophylaxis for intravitreal injections: a consecutive series of 18,839 injections by a single surgeon.
    Bhavsar AR; Sandler DR
    Retina; 2015 Apr; 35(4):783-8. PubMed ID: 25526099
    [TBL] [Abstract][Full Text] [Related]  

  • 8. No cases of endophthalmitis after 20,293 intravitreal injections in an operating room setting.
    Brynskov T; Kemp H; Sørensen TL
    Retina; 2014 May; 34(5):951-7. PubMed ID: 24317292
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of bevacizumab after topical, subconjunctival, and intravitreal administration in rabbits.
    Nomoto H; Shiraga F; Kuno N; Kimura E; Fujii S; Shinomiya K; Nugent AK; Hirooka K; Baba T
    Invest Ophthalmol Vis Sci; 2009 Oct; 50(10):4807-13. PubMed ID: 19324856
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Using intravitreal bevacizumab (Avastin
    Kumar A; Ravani R
    Indian J Ophthalmol; 2017 Jul; 65(7):545-548. PubMed ID: 28724808
    [No Abstract]   [Full Text] [Related]  

  • 11. ACCURACY AND PRECISION OF INTRAVITREAL INJECTIONS OF ANTI-VASCULAR ENDOTHELIAL GROWTH FACTOR AGENTS IN REAL LIFE: What Is Actually in the Syringe?
    Loewenstein I; Goldstein M; Moisseiev J; Moisseiev E
    Retina; 2019 Jul; 39(7):1385-1391. PubMed ID: 29659411
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of ocular volume and lens status on pharmacokinetics and duration of action of intravitreal vascular endothelial growth factor inhibitors.
    Krohne TU; Muether PS; Stratmann NK; Holz FG; Kirchhof B; Meyer CH; Fauser S
    Retina; 2015 Jan; 35(1):69-74. PubMed ID: 25077535
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetics of intravitreal ranibizumab (Lucentis).
    Bakri SJ; Snyder MR; Reid JM; Pulido JS; Ezzat MK; Singh RJ
    Ophthalmology; 2007 Dec; 114(12):2179-82. PubMed ID: 18054637
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Outcomes and risk factors associated with endophthalmitis after intravitreal injection of anti-vascular endothelial growth factor agents.
    Shah CP; Garg SJ; Vander JF; Brown GC; Kaiser RS; Haller JA;
    Ophthalmology; 2011 Oct; 118(10):2028-34. PubMed ID: 21705087
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A one-year follow-up study of ocular and systemic complications of intravitreal injection of bevacizumab (Avastin).
    Fasih U; Shaikh N; Rahman A; Sultan S; Fehmi MS; Shaikh A
    J Pak Med Assoc; 2013 Jun; 63(6):707-10. PubMed ID: 23901669
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Safety of repeat intravitreal injections of bevacizumab versus ranibizumab: our experience after 2,000 injections.
    Ladas ID; Karagiannis DA; Rouvas AA; Kotsolis AI; Liotsou A; Vergados I
    Retina; 2009 Mar; 29(3):313-8. PubMed ID: 19287287
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Incidence of endophthalmitis and use of antibiotic prophylaxis after intravitreal injections.
    Cheung CS; Wong AW; Lui A; Kertes PJ; Devenyi RG; Lam WC
    Ophthalmology; 2012 Aug; 119(8):1609-14. PubMed ID: 22480743
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicted biologic activity of intravitreal bevacizumab.
    Stewart MW
    Retina; 2007; 27(9):1196-200. PubMed ID: 18046224
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Concentrations of unbound bevacizumab in the aqueous of untreated fellow eyes after a single intravitreal injection in humans.
    Meyer CH; Krohne TU; Holz FG
    Acta Ophthalmol; 2012 Feb; 90(1):68-70. PubMed ID: 20163369
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bilateral simultaneous intravitreal injections in the office setting.
    Bakri SJ; Risco M; Edwards AO; Pulido JS
    Am J Ophthalmol; 2009 Jul; 148(1):66-9.e1. PubMed ID: 19403114
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.